Naturally Splendid Announces Application for Management Cease Trade Order

Naturally Splendid Announces Application for Management Cease Trade Order

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRA:50N)(TSX-V:NSP)(OTC PINK:NSPDF) announces that it has made an application to the British Columbia and Alberta Securities Commission to approve a temporary management cease trade order ("MCTO") under National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"), which, if granted, will prohibit trading securities by the Company by the Chief Executive Officer and Chief Financial Officer of the Corporation until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted. During the period in which the MCTO is effective, the general public, who are not insiders of the Company, will continue to be able to trade in the Company's listed securities. The MCTO application has been made but there is not guarantee or assurance that the MCTO will be granted

The Company expects it will be unable to file its audited financial statements for the year ended December 31, 2021, and the management's discussion and analysis and related Chief Executive Officer and Chief Financial Officer certificates for this period (collectively, the "Required Filings") before the May 2, 2022 filing deadline (the "Filing Deadline").

The Company's failure to file its Required Filings by the Filing Deadline is due to a combination of factors including the recent resignation of the Company's former auditor Smythe LLP on December 13, 2021.

The Company anticipates that it will be in a position to remedy the default by filing the Required Filings on or about June 30, 2022. The MCTO will be in effect until the Required Filings are filed.

The Company intends to satisfy the provision of the alternative information guidelines set out in sections 9 and 10 of NP-12-203 as long as the Required Filings are outstanding.

Naturally Splendid CFO Mr. George Ragogna states, "It has been a progressive first forty-five (45) days as CFO of Naturally Splendid. In my first month and a half as CFO, I have completed reviews of the financial reporting systems, ongoing operations, as well as the capital build-out required to accommodate the manufacturing of our extensive range of plant-based entrees. Having completed initial reviews, senior management will be implementing strategic plans to optimize shareholder value."

The Company continues to advance our plant-based manufacturing and distribution business by recently extending our agreement with Flexitarian Foods Pty. Ltd., a division of Australia's largest plant-based food manufacturer, from being the exclusive Canadian manufacturer and distributor, to now include exclusive rights to the Plantein trademark in Canada (News Release April 12, 2022). The Plantein trademark, initially established in Australia, is now being exported to regions of the European Union (EU), the United Arab Emirates (UAE) and now across Canada.

Naturally Splendid CFO Mr. George Ragogna reports, "While our core business strategy continues to be aimed towards manufacturing plant-based entrees, including the build-out of new manufacturing and packaging lines, it is fiscally prudent to conduct a review and analysis of existing operations. I am pleased to report that with the involvement of senior management, we have identified significant savings in monthly overheads including a reduction in staffing levels, reduction in certain services as well as implementation of efficiency measures operationally. We will continue to strive to be prudent with our overheads and capital spends while building out our plant-based entrée business and look forward to providing timely updates".

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a plant-based food manufacturing and technology company that produces and distributes nutritious and delicious plant-based commodity products.

Founded in 2010, the Company operates a Safe Quality Food Level 2 certified food manufacturing facility located just outside Vancouver, BC in Canada, focusing on producing an extensive range of plant-based entrees.

Naturally Splendid has an exclusive 10-year manufacturing and distribution agreement for Canada with a division of Australia's largest plant-based food manufacturer, Flexitarian Foods Pty. Ltd.

In addition to producing the Company's own branded products, Naturally Splendid provides contract manufacturing services and private labeling for a variety of nutritional plant-based food products destined for multiple distribution channels.

The Company has established healthy, functional foods under brands such as Natera Sportâ„¢, Natera Hemp Foodsâ„¢, CHIIâ„¢, Elevate Meâ„¢ and Woods Wild Barâ„¢. The Company launched Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

Naturally Splendid maintains a relationship Plasm Pharmaceutical, a company that has been approved for conducting a phase 2 clinical trial approved by Health Canada for the treatment of COVID-19.

NSE has also developed proprietary technologies for the extraction of healthy omega 3 and 6 oils, as well as a protein concentrate from hemp.

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
President, Director

Contact Information
Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTC PINK; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; customers will complete on sales contracts; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE:Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/697608/Naturally-Splendid-Announces-Application-for-Management-Cease-Trade-Order

News Provided by ACCESSWIRE via QuoteMedia

NSP:CA
The Conversation (0)
Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin states, "As we continue to focus our efforts and resources on PlanteinTM Plant-Based Foods and our ten (10) year exclusive manufacturing and distribution agreement with Flexitarian Foods PTY Ltd., there have been many positives as well as a number of challenges. The positives include our recent launch into retail, and the return to trade shows where are products have been getting exceptional reviews, as well as our expanding relations with our national distributors. However, the Company has experienced significant challenges as well, the most notable being the continued delay of customized manufacturing lines being assembled in Shanghai, China. The delay to date has been due to a combination of shortage of computer chips, combined with on-going Covid challenges and subsequent quarantining in Shanghai".

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Management Update

Naturally Splendid Management Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that Mr. George Ragogna will be stepping down as CFO and a Member of the Board of Directors effective immediately

Mr. Ragogna will remain with the Company as an Independent Consultant, focusing his efforts on logistics and our inventory management control system. Mr. Bryan Carson, current Executive VP and Company Co-founder, will step in as interim CFO.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Presents at Grocery Innovations Canada Trade Show in Toronto

Naturally Splendid Presents at Grocery Innovations Canada Trade Show in Toronto

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce the Company presented the PlanteinTM line of plant-based entrees at the Grocery Innovations Canada trade show on October 25 and October 26, 2022, at the Toronto Congress Centre

Grocery Innovations Canada, is one of Canada's premier grocery trade show events, bringing together manufacturers and retailers from not only Eastern Canada, but in fact from all across the country. Naturally Splendid featured the PlanteinTM line of plant-based products to retailers and distributors from across the country.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Vegan Supply to Distribute Plantein Through Foodservice Network & Sell in Retail Store

Vegan Supply to Distribute Plantein Through Foodservice Network & Sell in Retail Store

VANCOUVER, BC / ACCESSWIRE/ September 6, 2022 / Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC Pink:NSPDF) is pleased to announce that Vegan Supply will carry a selection of PlanteinTM products for its retail and foodservice customers.

Vegan Supply, a Vancouver based company with both retail and foodservice distribution, began business in 2015 as the world's largest e-commerce marketplace exclusively providing their retail customers and foodservice clients with high-quality vegan products. Vegan Supply is listing five (5) PlanteinTM plant-based entrees: Nuggets, Schnitzel, Crumbed Tenders, Sweet Chili Tenders, and Crispy Burgers. The PlanteinTM line of products will be available through Vegan Supply's retail store in Vancouver, BC, their e-commerce platform, and marketed to their foodservice distribution network.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
CORRECTION: Naturally Splendid Reports Second Quarter Results for 2022

CORRECTION: Naturally Splendid Reports Second Quarter Results for 2022

This release acts as a correction for the release posted on 8/29/2022 at 10:30 PM EDT from Naturally Splendid Enterprises Ltd. announcing its second quarter results for 2022 due to an error in comments stated

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the six months ended June 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

BLINCYTO® ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%

Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA

Investment Establishes Second Facility in Holly Springs ; Builds on Previous $550M Commitment

Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina . This brings the company's total planned investment in Holly Springs to more than $1.5 billion building on its previously announced $550 million commitment.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday Dec. 5, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024 . Peter Griffith executive vice president and chief financial officer at Amgen, Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Download the PDF here.

Latest Press Releases

Related News

×